We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+4.63%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+763.65%
AUM
$77.1B
AUM Growth
-$1.68B
(-2.1%)
Cap. Flow
-$2.68B
Cap. Flow
% of AUM
-3.48%
Top 10 Holdings %
Top 10 Hldgs %
16.75%
Holding
3,716
New
704
Increased
979
Reduced
1,056
Closed
911
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$626M |
| 2 |
Warner Bros
WBD
|
+$447M |
| 3 |
Apple
AAPL
|
+$436M |
| 4 |
RTX Corp
RTX
|
+$434M |
| 5 |
Constellation Brands
STZ
|
+$320M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.13B |
| 2 |
Microsoft
MSFT
|
+$502M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$436M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$415M |
| 5 |
Electronic Arts
EA
|
+$388M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.75% |
| 2 | Industrials | 9.36% |
| 3 | Consumer Discretionary | 8.52% |
| 4 | Healthcare | 7.75% |
| 5 | Financials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVLA
901
Palvella Therapeutics
PVLA
$2.05B
| $12.1M | 0.02% |
96,726
-12,154
| -11% | -$1.27M |
|
902
Aquestive Therapeutics
AQST
$460M
| $12M | 0.02% |
2,900,570
+1,929,631
| +199% | +$7.83M |
|
903
CALL
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.54B
| $12M | 0.02% |
368,500
+351,600
| +2,080% | +$11.8M |
|
904
Doximity
DOCS
$3.74B
| $11.9M | 0.02% |
+512,249
| New | +$16M |
|
905
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.9B
| $11.9M | 0.02% |
150,000
+94,017
| +168% | +$7.56M |
|
906
Nike
NKE
$61.9B
| $11.9M | 0.02% |
225,461
+191,450
| +563% | +$11.6M |
|
907
ManpowerGroup
MAN
$2.38B
| $11.9M | 0.02% |
404,169
+126,790
| +46% | +$3.77M |
|
908
CALL
Altria Group
MO
$116B
| $11.9M | 0.02% |
+180,300
| New | +$11.6M |
|
909
PUT
American Express
AXP
$228B
| $11.9M | 0.02% |
39,200
-66,700
| -63% | -$22.4M |
|
|
NP
910
Neptune Insurance Holdings
NP
$4.34B
| $11.8M | 0.02% |
489,171
-507,090
| -51% | -$11.7M |
|
911
DoubleVerify
DV
$1.68B
| $11.8M | 0.02% |
1,244,679
+1,230,820
| +8,881% | +$12.6M |
|
912
Korro Bio
KRRO
$149M
| $11.8M | 0.02% |
+1,040,054
| New | +$11.4M |
|
913
Green Plains
GPRE
$1.2B
| $11.8M | 0.02% |
715,374
+517,990
| +262% | +$7.04M |
|
914
Reynolds Consumer Products
REYN
$5.31B
| $11.8M | 0.02% |
555,518
+233,601
| +73% | +$5.36M |
|
915
PUT
Applied Materials
AMAT
$408B
| $11.7M | 0.02% |
34,200
-313,700
| -90% | -$106M |
|
916
Lumen
LUMN
$6.7B
| $11.7M | 0.02% |
1,678,951
-490,195
| -23% | -$3.71M |
|
917
Life Time Group Holdings
LTH
$10.1B
| $11.7M | 0.02% |
432,559
-376,102
| -47% | -$10.4M |
|
918
CAMP4 Therapeutics
CAMP
$182M
| $11.6M | 0.02% |
2,632,437
+195,537
| +8% | +$928K |
|
919
Sutro Biopharma
STRO
$408M
| $11.6M | 0.02% |
465,792
+235,743
| +102% | +$4.26M |
|
920
PUT
ScottsMiracle-Gro
SMG
$3.88B
| $11.6M | 0.02% |
+190,000
| New | +$12.3M |
|
|
SNDK
921
PUT
Sandisk
SNDK
$184B
| $11.5M | 0.01% |
+18,100
| New | +$10.2M |
|
922
Visteon
VC
$2.75B
| $11.5M | 0.01% |
125,982
+93,280
| +285% | +$8.82M |
|
923
PUT
Texas Instruments
TXN
$252B
| $11.5M | 0.01% |
59,100
+40,000
| +209% | +$8.1M |
|
924
Warrior Met Coal
HCC
$4.22B
| $11.5M | 0.01% |
+123,082
| New | +$11.1M |
|
925
Diodes
DIOD
$3.8B
| $11.4M | 0.01% |
166,848
+162,275
| +3,549% | +$10.2M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Balyasny Asset Management held 3,716 positions worth $77.1B, down 2.1% from $78.8B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Balyasny Asset Management withdrew a net $2.68B in Q1 2026, closing 911 positions and reducing 1,056 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $1.13B position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Balyasny Asset Management opened a new position in Silicon Laboratories worth $257M.
- Balyasny Asset Management's largest Q1 2026 buy was Silicon Laboratories: 1,233,893 shares worth $257M.
- Balyasny Asset Management added most to Meta Platforms (Facebook) in Q1 2026, an estimated $626M increase.
- Balyasny Asset Management's biggest Q1 2026 reduction was Microsoft, cutting an estimated $502M.
- Balyasny Asset Management fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $1.13B.
- Balyasny Asset Management's ten largest holdings make up 17% of its $77.1B portfolio in Q1 2026.
- Balyasny Asset Management opened 704 new positions and closed 911 in Q1 2026.
- Balyasny Asset Management's portfolio value fell 2.1% quarter-over-quarter to $77.1B.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.